Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Edward D. Ball, MD
University of California, San Diego
Principal Investigator - Hugo Fernandez, MD
University of Miami
Principal Investigator - John DiPersio, MD
Washington University Medical Center, Siteman Cancer Center
Principal InvestigatorKOL profile → - Jonathan Kolitz, MD, FACP
North Shore University Hospital
Principal Investigator - Maria Baer
Roswell Park Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, San Diego
La Jolla, California, United States
- University of Miami Health Center
Miami, Florida, United States
- Washington University Medical Center (siteman Cancer Center)
St Louis, Missouri, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- North Shore University Hospital
Lake Success, New York, United States
- M. D. Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2004
- Primary completion
- 31 May 2007
- Completion
- 31 May 2007
- Last update posted
- 18 Sept 2014
- Registered enrollment
- 53
- Registry id
- NCT00074737
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.